
|Articles|May 12, 2022
Daily Medication Pearl: Delafloxacin (Baxdela)
Author(s)Saro Arakelians, PharmD
Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.
Advertisement
Medication Pearl of the Day: Delafloxacin (Baxdela)
Indication: Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.
Insight:
- Dosing: Administer delafloxacin for injection 300 mg by intravenous (IV) infusion over 60 minutes, every 12 hours, or a 450-mg delafloxacin tablet orally every 12 hours for 5 to 14 days total duration.
- Dosage forms: For Injection 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single dose vial for reconstitution and further dilution before IV infusion.
- Adverse events: Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.
- Mechanism of action: Delafloxacin is an antibacterial drug.
- Manufacturer: Melinta Therapeutics
Reference
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























